<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210809052118N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-13</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Effect of wet-cupping in treatment oligomenorrhea</public_title>
      <acronym>Pcos</acronym>
      <scientific_title>Effects of wet-cupping on calf muscles on improving amenorrhea and oligomenorrhea in patients with polycystic ovary syndrome (PCOs)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>92</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70117</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sampling is done in a non-random, easy way (available sample) and the classification of samples to be assigned to treatment is done in a Block randomization. In other words, people are randomly assigned to the treatment and control groups with equal numbers. The randomization unit is considered individual. RAS statistical software was used as a block randomization tool.</study_design>
      <phase>3</phase>
      <hc_freetext>Polycystic Ovarian Syndrom.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Performing cupping of both legs once and on the 26th day of menstrual cycle- At first, the patient will be given the necessary advice about observing the necessary pre-cupping, such as food precautions. The patient sits on a chair next to the bed, the position of the leg cupping that the posterior-lateral part of the leg and the leg is equal to one foot of the hand above the outer ankle, with the cup, connected to the suction cup. The suction takes a few seconds and 30 times. Repeated cupping before cupping causes partial anesthesia and reduces the amount of pain caused by razor. Then، by observing the sterile tips with a bistorial blade No. 11 along the skin lines (almost oblique)، about 10 to 15 subtle superficial incisions are made on the epidermis and dermis surface. The cupping cup is placed again in the area and with three re-suction in it, excess blood is removed. At the end the area is bandaged after sterilization and recommendations are given for care. Intervention 2: Control group: Two groups receive 500 mg of metformin twice daily for three months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The main result and some specific goals are published.
Including: the number of menstrual cycles as The main result of the study and the effect of some specific goals such as (increasing the length of the bleeding period - improving the Quality of Life -  bleeding in the next month).
Confidentiality of information is maintained.
Personal information is not published.
Only information related to primary and secondary outcomes will be used and shared for analysis.

When:
6 months after the publication of the article, the data will be published.

To whom:
Students and professors of universities of medical sciences and scientific institutions affiliated to universities and the Ministry of Health and Medical Education

Conditions:
The reasons for using the data it is necessary to obtain the source for the purpose of use 
the request and signature of the responsible official of the requesting institution

Where to obtain:
The scientific officer of the project- Correspondence to the declared e-mail
tansaz_mojgan@yahoo.com

How to obtain:
Sending a written request with the signature of the official of the requesting institution to the e-mail address of the scientific officer of the project - confirmation of the Requirements to be met (obligation to mention the source) - checking the request and sending the data within a maximum of one month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mojgan Tansaz</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 8, Shams Alley, in front of Tovanir,Vali Asr St., Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1516745811</zip>
        <telephone>+98 21 8877 3521</telephone>
        <email>tansaz_mojgan@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahrzad Zadeh Modares</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Boroujerdi St., Shishegar Khaneh St., Fadaiyan Eslam St., Shoosh Sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1185817311</zip>
        <telephone>+98 21 5631 4935</telephone>
        <email>mahdiyeh_hospital@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women with polycystic ovarian- age between 18 and 35 with menstrual disorder-who have menstrual cycles of at least 60 days in the last year.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patients using metformin or every hormonal drugs, including herbal and phytoestrogens, in the last three months
Positive BHCG titer or lactating women
People with coagulation disorders and anemia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic Ovarian Syndrom</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Performing cupping of both legs once and on the 26th day of menstrual cycle- At first, the patient will be given the necessary advice about observing the necessary pre-cupping, such as food precautions. The patient sits on a chair next to the bed, the position of the leg cupping that the posterior-lateral part of the leg and the leg is equal to one foot of the hand above the outer ankle, with the cup, connected to the suction cup. The suction takes a few seconds and 30 times. Repeated cupping before cupping causes partial anesthesia and reduces the amount of pain caused by razor. Then، by observing the sterile tips with a bistorial blade No. 11 along the skin lines (almost oblique)، about 10 to 15 subtle superficial incisions are made on the epidermis and dermis surface. The cupping cup is placed again in the area and with three re-suction in it, excess blood is removed. At the end the area is bandaged after sterilization and recommendations are given for care.</i_keyword>
      <i_keyword>Control group: Two groups receive 500 mg of metformin twice daily for three months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Frequency of menstrual cycle. Timepoint: First day and weeks 2, 4, 6, 8, 10, 12. Method of measurement: Asking the patient.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Length of bleeding period. Timepoint: The first day and weeks 2، 4، 6، 8،10،12. Method of measurement: Ask the patient based on the number of days of bleeding.</sec_outcome>
      <sec_outcome>The amount of excess hair(hirsutism). Timepoint: The first day and weeks 4، 8، 12. Method of measurement: the Freeman Galloway chart.</sec_outcome>
      <sec_outcome>Quality of life of patients with polycystic ovary syndrome. Timepoint: The first day and weeks 4، 8، 12. Method of measurement: PCOSQ-50 Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-30</approval_date>
        <contact_name>The specialized committee of ethics in biomedical research</contact_name>
        <contact_address>Shahid Beheshti University of Medical Sciences, No.2, Aarabi St., Daneshjoo Blvd., Velenjak, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
